Marco Davila, MD, PhD, medical oncologist, Moffitt Cancer Center, discusses MDS as an immunoresponsive disease and applying immunotherapies to MDS.
Roxadustat Misses Efficacy End Point in Phase 3 MDS Study
May 12th 2023The proportion of patients with myelodysplastic syndromes who achieved red blood cell transfusion independence in the first 28 weeks was 47.5% for patients given roxadustat vs 33.3% for patients given placebo for the treatment of anemia.
Read More
Nivolumab Combinations Improve Survival But Are Not Cost-Prohibitive in Advanced ESCC
May 9th 2023An analysis of data from the CheckMate-648 trial sows that while adding nivolumab to either ipilimumab or chemotherapy for patients with advanced esophageal squamous cell carcinoma improves survival outcomes, their current price is not cost-effective for first-line treatment.
Read More
2 Clarke Drive
Cranbury, NJ 08512